NORVIR

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug NORVIR contains one active pharmaceutical ingredient (API):

1	Ritonavir UNII O3J8G9O825 - RITONAVIR
	Ritonavir is an orally active peptidomimetic inhibitor of the HIV-1 and HIV-2 aspartyl proteases. Inhibition of HIV protease renders the enzyme incapable of processing the gag-pol polyprotein precursor which leads to the production of HIV particles with immature morphology that are unable to initiate new rounds of infection. Ritonavir has selective affinity for the HIV protease and has little inhibitory activity against human aspartyl proteases. Pharmacokinetic enhancement by ritonavir is based on ritonavir’s activity as a potent inhibitor of CYP3A-mediated metabolism.
	Read more about Ritonavir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NORVIR Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AE03	Ritonavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10273Q
BR	Câmara de Regulação do Mercado de Medicamentos	543715070001617, 543718100003903
CA	Health Products and Food Branch	02357593
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	2-MEE-1213
EE	Ravimiamet	1109281, 1197873, 1285961, 1460113, 1460124, 1504482, 1580206, 1696686
ES	Centro de información online de medicamentos de la AEMPS	196016009, 96016005
FI	Lääkealan turvallisuus- ja kehittämiskeskus	036290
FR	Base de données publique des médicaments	65102533, 67851855
GB	Medicines & Healthcare Products Regulatory Agency	171734, 329059
HK	Department of Health Drug Office	61528
IL	מִשְׂרַד הַבְּרִיאוּת	7219
JP	医薬品医療機器総合機構	6250011F1024
LT	Valstybinė vaistų kontrolės tarnyba	1008592, 1008594, 1029813, 1053215, 1053216, 1058042, 1061352, 1080819
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	244M2012
NL	Z-Index G-Standaard, PRK	129690, 45128, 94064
NZ	Medicines and Medical Devices Safety Authority	13812
PL	Rejestru Produktów Leczniczych	100223530, 100387881
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64691001
SG	Health Sciences Authority	14288P
TR	İlaç ve Tıbbi Cihaz Kurumu	8680656080179, 8680656080308, 8699548191084
US	FDA, National Drug Code	0074-1940, 0074-3333, 0074-3399, 53808-1119, 67296-1234
ZA	Health Products Regulatory Authority	31/20.2.8/0216, 31/20.2.8/0217, 44/20.2.8/0128, 51/20.2.8/0154